Bringing the Oncology Community Together

Dr. Sartor on Combining Radium-223 and Provenge

Oliver Sartor, MD
Published Online: Wednesday, April 25, 2012
Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses a new trial concept that seeks to combine the radiopharmaceutical radium-223 chloride (Alpharadin) and the immunotherapy sipuleucel-T (Provenge), for men with castration-resistant prostate cancer.

Sartor explains the rationale behind this combination was based on the ability of radium-223 to release antigens, which makes the cancer cells more susceptible to immunotherapies, such as sipuleucel-T. The initial trial will likely be a small proof of concept study to gather evidence on the efficacy of the combination before it is tested in a larger population.

The companies that develop sipuleucel-T (Dendreon Corporation) and radium-223 (Bayer Pharma AG) have already agreed to participate in the trial.

Related Articles
Early Detection of Metastatic Prostate Cancer
In this segment, panelists discuss advanced imaging techniques that can be used to detect metastases earlier for patients with castration-resistant prostate cancer.
Adding ADT to RT Reduces Risk of Progression in Localized Prostate Cancer
Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.
Pretreatment Genetic Test Predicts Recurrence in Prostate Cancer
A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.